A Phase 2, multicenter, open-label, non-randomized, proof-of-concept study evaluating the efficacy, safety, and tolerability of SAR445088 in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)
Study of SAR445088 in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sponsor: Sanofi
Enrolling: Male and Female Patients
IRB Number: AAAT9079
U.S. Govt. ID: NCT04658472
Contact: Raisy Fayerman: 212-305-6035 / rf2632@cumc.columbia.edu
Additional Study Information: This study is a global multicenter, Phase 2, open-label, PoC study evaluating the efficacy, safety, and tolerability of SAR445088 administered to 3 subpopulations of patients with chronic inflammatory demyelinating polyneuropathy (CIDP): patients who are being treated with SOC therapies defined as intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg), or corticosteroids; patients with CIDP who are refractory to SOC; and patients with CIDP who are nave to SOC. Adults 18 years of age at the time of signing the informed consent.
This study is closed
Investigator
Thomas Brannagan, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with CIDP? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Raisy Fayerman
rf2632@cumc.columbia.edu
212-305-6035